- Home
- INCY vs TPR Comparison
INCY vs TPR Comparison
Compare INCY & TPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INCY | TPR |
|---|---|---|
| Founded | 1991 | 1941 |
| Country | United States | United States |
| Employees | 2844 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.7B | 22.0B |
| IPO Year | 1994 | 2000 |
Fundamental Metrics
Financial Performance| Metric | INCY | TPR |
|---|---|---|
| Price | $120.67 | $116.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 28 | 21 |
| Target Price | $130.63 | ★ $161.16 |
| AVG Volume (30 Days) | 1.8M | ★ 1.9M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 1.57% |
| EPS Growth | ★ 4173.33 | 786.59 |
| EPS | 0.50 | ★ 7.27 |
| Revenue | $3,394,635,000.00 | ★ $5,880,000,000.00 |
| Revenue This Year | $18.06 | $6.67 |
| Revenue Next Year | $3.30 | $5.40 |
| P/E Ratio | $79.26 | ★ $16.18 |
| Revenue Growth | 13.67 | ★ 31.01 |
| 52 Week Low | $89.25 | $93.00 |
| 52 Week High | $132.60 | $164.80 |
Technical Indicators
Market Signals| Indicator | INCY | TPR |
|---|---|---|
| Relative Strength Index (RSI) | 56.42 | 52.04 |
| Support Level | $115.77 | $111.37 |
| Resistance Level | $130.53 | $120.88 |
| Average True Range (ATR) | 3.63 | 3.02 |
| MACD | 0.95 | 0.37 |
| Stochastic Oscillator | 79.39 | 61.56 |
Price Performance
Historical ComparisonAbout INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
About TPR Tapestry Inc.
Based in New York City, Tapestry is the parent company of accessories and fashion brand Coach, which accounted for 86% of its revenue and all its operating profit in fiscal 2026. Coach was founded as a leathergoods company in 1941, and handbags represented 58% of its fiscal 2026 revenue. Coach products are sold through nearly 1,000 company-owned stores, company-operated digital channels, and wholesale partners in North America, Asia, and Europe. Tapestry also owns Kate Spade (13% of fiscal 2026 revenue), which operates more than 300 worldwide stores and generated 55% of its revenue from handbags in fiscal 2025. Founded in 1993, Kate Spade is known for its colorful patterns and graphics.